How Tumour Necrosis Factor Blockers Interfere with Tuberculosis Immunity

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2010 May 25

PMID 20491796

Citations 126

Authors

J Harris

J Keane

Affiliations

Soon will be listed here.

Abstract

Tumour necrosis factor (TNF) is a potent inflammatory cytokine that plays an important role in immunity to numerous bacterial infections, including Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) in humans. Infliximab, adalimumab, certolizumab pegol and etanercept are anti-TNF agents used to treat a range of inflammatory/autoimmune diseases, such as rheumatoid arthritis. The use of some of these drugs has been linked to reactivation TB. In addition to blocking TNF-mediated immune responses, some anti-TNF drugs have been found to interfere with innate immune responses, such as phagolysosomal maturation and monocyte apoptosis, as well as cell-mediated responses, including interferon-gamma secretion by memory T cells, complement-mediated lysis of Mtb-reactive CD8+ T cells and increased regulatory T cell activity. This review summarizes some of the reported effects of TNF blockers on immune cell responses in the context of the observed clinical data on TB reactivation in patients on anti-TNF therapy.

Citing Articles

Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.

Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D Front Immunol. 2024; 15:1427559.

PMID: 39717773 PMC: 11663721. DOI: 10.3389/fimmu.2024.1427559.

Human airway macrophages are metabolically reprogrammed by IFN-γ resulting in glycolysis-dependent functional plasticity.

Cox D, Connolly S, O Maoldomhnaigh C, Brugman A, Sandby Thomas O, Duffin E Elife. 2024; 13.

PMID: 39620891 PMC: 11611294. DOI: 10.7554/eLife.98449.

Tumor necrosis factor superfamily signaling: life and death in cancer.

Ababneh O, Nishizaki D, Kato S, Kurzrock R Cancer Metastasis Rev. 2024; 43(4):1137-1163.

PMID: 39363128 PMC: 11554763. DOI: 10.1007/s10555-024-10206-6.

Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent.

Sultana A, Migliori G, DAmbrosio L, Garcia-Garcia J, Silva D, Rendon L J Bras Pneumol. 2024; 50(4):e20240082.

PMID: 39356910 PMC: 11449592. DOI: 10.36416/1806-3756/e20240082.

Editorial: Women in cytokines and soluble mediators in immunity.

Boraschi D, Penton-Rol G, Amodu O, Blomberg M Front Immunol. 2024; 15:1395165.

PMID: 38550586 PMC: 10973138. DOI: 10.3389/fimmu.2024.1395165.

References

Scott-Browne J, Shafiani S, Tucker-Heard G, Ishida-Tsubota K, Fontenot J, Rudensky A . Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med. 2007; 204(9):2159-69. PMC: 2118702. DOI: 10.1084/jem.20062105. View

Laochumroonvorapong P, Paul S, Elkon K, Kaplan G . H2O2 induces monocyte apoptosis and reduces viability of Mycobacterium avium-M. intracellulare within cultured human monocytes. Infect Immun. 1996; 64(2):452-9. PMC: 173785. DOI: 10.1128/iai.64.2.452-459.1996. View

Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B . The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995; 83(5):793-802. DOI: 10.1016/0092-8674(95)90192-2. View

Schaible U, Winau F, Sieling P, Fischer K, Collins H, Hagens K . Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med. 2003; 9(8):1039-46. DOI: 10.1038/nm906. View

Ling Y, Shaw M, Ayala C, Coppens I, Taylor G, Ferguson D . Vacuolar and plasma membrane stripping and autophagic elimination of Toxoplasma gondii in primed effector macrophages. J Exp Med. 2006; 203(9):2063-71. PMC: 2118399. DOI: 10.1084/jem.20061318. View

Nunez Martinez O, Ripoll Noiseux C, Martin J, Gonzalez Lara V, Gregorio Maranon H . Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol. 2001; 96(5):1665-6. DOI: 10.1111/j.1572-0241.2001.03836.x. View

Harris J, Hope J, Keane J . Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis. 2008; 198(12):1842-50. DOI: 10.1086/593174. View

Jia L, Dourmashkin R, Allen P, Gray A, Newland A, Kelsey S . Inhibition of autophagy abrogates tumour necrosis factor alpha induced apoptosis in human T-lymphoblastic leukaemic cells. Br J Haematol. 1997; 98(3):673-85. DOI: 10.1046/j.1365-2141.1997.2623081.x. View

Dieli F, Troye-Blomberg M, Ivanyi J, Fournie J, Bonneville M, Peyrat M . Vgamma9/Vdelta2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur J Immunol. 2000; 30(5):1512-9. DOI: 10.1002/(SICI)1521-4141(200005)30:5<1512::AID-IMMU1512>3.0.CO;2-3. View

10.

Chakravarty S, Zhu G, Tsai M, Mohan V, Marino S, Kirschner D . Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun. 2008; 76(3):916-26. PMC: 2258824. DOI: 10.1128/IAI.01011-07. View

11.

Bean A, Roach D, Briscoe H, France M, Korner H, Sedgwick J . Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999; 162(6):3504-11. View

12.

Schaible U, Schlesinger P, Russell D . Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol. 1998; 160(3):1290-6. View

13.

Black R, Rauch C, Kozlosky C, Peschon J, Slack J, Wolfson M . A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997; 385(6618):729-33. DOI: 10.1038/385729a0. View

14.

Netea M, Radstake T, Joosten L, van der Meer J, Barrera P, Kullberg B . Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum. 2003; 48(7):1853-7. DOI: 10.1002/art.11151. View

15.

Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A . Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008; 58(5):1248-57. DOI: 10.1002/art.23447. View

16.

Agnholt J, Kaltoft K . Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine. 2001; 15(4):212-22. DOI: 10.1006/cyto.2001.0919. View

17.

Wajant H, Pfizenmaier K, Scheurich P . Tumor necrosis factor signaling. Cell Death Differ. 2003; 10(1):45-65. DOI: 10.1038/sj.cdd.4401189. View

18.

Vergne I, Chua J, Deretic V . Mycobacterium tuberculosis phagosome maturation arrest: selective targeting of PI3P-dependent membrane trafficking. Traffic. 2003; 4(9):600-6. DOI: 10.1034/j.1600-0854.2003.00120.x. View

19.

Flynn J, GOLDSTEIN M, Chan J, Triebold K, Pfeffer K, Lowenstein C . Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995; 2(6):561-72. DOI: 10.1016/1074-7613(95)90001-2. View

20.

Haider A, Cardinale I, Whynot J, Krueger J . Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc. 2007; 12(1):9-15. DOI: 10.1038/sj.jidsymp.5650032. View